Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calprotectin-Directed Adalimumab Maintenance in Crohn's Disease
NCT01674413Phase 3Withdrawn
- Sponsor
- Peter Higgins
- Start
- Oct 2013
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab in Crohn's disease, sponsored by Peter Higgins. Planned start Oct 2013; status: withdrawn.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01674413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674413.